News

Quebec announces policy on rare diseases

Muscular Dystrophy Canada applauds the Quebec government for leading the way towards a rare disease strategy for Canadians by announcing its own rare disease policy.

The Minister of Health and Social Services, Christian Dubé, announced the establishment of the first Quebec policy for rare diseases on June 6, 2022. The policy aims to optimize the accessibility of quality health care and services that are safe, fair, inclusive and adapted to the specific needs of patients with rare diseases and their families.

“This is a great step forward for the rare disease community, and will perhaps motivate other provinces to do the same,” said Stacey Lintern, CEO, Muscular Dystrophy Canada. “Having our provinces prioritizing and working on rare disease policies, and collaborating with each other is the next big step towards developing a national rare disease strategy.”

Read the full release
(French only)

All Canadians deserve access to life-changing treatments

While therapies exist for spinal muscular atrophy (SMA), many of them are out of reach for adults. Recently, a CTV article featuring Nouma Hammash highlighted the disparity that exists depending on your age, and where you live in Canada.

“For instance, in Quebec and Saskatchewan MDC clients, like Nouma, have access to life-changing drugs. In other provinces and territories that is not the case. Muscular Dystrophy Canada (MDC) urges the government to give all adults access to these treatments because of the incredible outcomes that are possible,” said Stacey Lintern, CEO, Muscular Dystrophy Canada.

At a roundtable discussion, attended by twelve individuals affected by spinal muscular atrophy, from across the country, MDC heard that geographic location, age, lack of qualitative data and a piece-meal approach by governments all prevent Canadian adults from accessing treatments that could radically improve their quality of life.

“In a neuromuscular disorder like SMA, access to treatments are critical to achieving the best possible outcomes. For Canadians affected, it can mean the difference in how quickly a condition progresses and as a result, the way they walk, feed themselves and for some even breathe,” said Homira Osman, VP, Research and Public Policy, Muscular Dystrophy Canada.

If you would like to learn more about treatments and how to access them, please contact the Research Hotline at: research@muscle.ca.

You can also find information about access to treatments and submissions to government here: muscle.ca/services-support/advocacy/access-to-treatments

Disability Inclusion Action Plan consultations set to begin in May

Friday, May 6, 2022

Muscular Dystrophy Canada and Independent Living Canada are pleased to announce that consultations for the Disability Inclusion Action Plan, as part of their project “Bridging the Gap: Between a Lived Experiences and Policy: A Community-Led, Capacity Building and Knowledge-Exchange Approach to the Disability Inclusion Action Plan” funded through Employment and Social Development Canada (ESDC), begin this May!

The Pillar Leads together with their supporting organizations have been working diligently to roll-out consultations to ensure we reach out to persons with a lived experience of a disability, individuals with a disability, and hard-to-reach marginalized, intersectional, under-represented groups and stakeholders.

Accessibility is a key priority, and all consultations will be held in an accessible and safe environment.

For more information about the project:

Muscular Dystrophy Canada and Independent Living Canada partner to help lead the development of Canada’s first ever Disability Inclusion Action Plan

If you’d like to take part in the consultations, please contact DIAP Project Co-ordinator Catherine MacKinnon at: diap@ilc-vac.ca

Announcing Muscular Dystrophy Canada’s 2022 Research Grant Competition winners!

We are pleased to share that we are funding nine new clinical and translational science research projects focusing on spinal muscular atrophy, Duchenne and Becker muscular dystrophies, immune mediated neuropathies, congenital myasthenic syndromes, immune-mediated neuromuscular junction disorders, myotonic dystrophy, occulopharyngeal muscular dystrophy, spinal bulbar muscular atrophy (Kennedy disease), and other related neuromuscular disorders.

Thank you to our donors who helped make this possible and to our Research Grant Review Panels of researchers, clinicians and community members with lived experience who volunteered their time to carefully review and help narrow down applications to our final projects.

“Through these exciting projects, these talented and dedicated Canadian researchers will develop new methods for disease diagnosis, uncover novel insight into disease pathogenesis, and develop new treatments options, amongst other meritorious projects,” says Dr. Robin Parks, Chair of the Medical and Scientific Advisory Committee for Muscular Dystrophy Canada (MDC) and Chair of the Translational Science Review Panel. “Through their support of MDC, donors, patients and their families are helping fund outstanding research projects that will move neuromuscular research forward and ultimately improve care and quality of life for those affected by neuromuscular disorders – which aligns with MDC’s mission.”

“We are extremely pleased with breadth of proposals received to our call for clinical and translational science research proposals we received this year. This is a hopeful sign of the continued momentum and progress in neuromuscular research. The nine selected recipients show exemplary innovation, dedication and promise of potential impact for a wide range of neuromuscular disorders,” says Stacey Lintern, CEO of Muscular Dystrophy Canada. “Because of our incredible community, we are able to fill a critical gap in research funding. We know how much change is possible from Canadian researchers and we are continually working with our supporters to ensure we invest in meaningful ways.”

Thank you to the Canadian neuromuscular research community for putting forward impactful applications.

2022-2023 WINNERS:

  • Dr. Thomas Durcan, MD, The Royal Institution for the Advancement of Learning/McGill University
    Building a screenable human 3D neuromuscular junction model for neuromuscular disorders
  • Dr. Christopher Perry, MD, York University
    Mitochondrial-targeted therapies to improve Duchenne muscular dystrophy outcomes
  • Dr. Craig Campbell, MD, London Health Sciences Centre Research Inc. (Lawson Health Research Institute)
    Genome-wide DNA methylation profile in Duchenne Muscular Dystrophy
  • Dr. Michael Berger, MD, University of British Columbia
    Measuring balance in chronic inflammatory demyelinating polyneuropathy
  • Dr. Bernard Jasmin, MD, University of Ottawa
    Endurance training as a novel therapeutic strategy for Myotonic Dystrophy type 1
  • Dr. Jodi Warman-Chardon, MD, Ottawa Hospital Research Institute
    QP-OPMD: Quantitative MRI Imaging to Assess Progression in Oculopharyngeal Muscular Dystrophy
  • Dr. Kerri Schellenberg, MD, The University of Saskatchewan
    Exploring the impact of Spinal Bulbar Muscular Atrophy on persons self-identifying as Indigenous
  • Dr. Reshma Amin, MD, The Hospital for Sick Children Dr. Aaron Izenberg, MD, Sunnybrook Health Sciences Centre
    The Transition of TEENagers with Spinal Muscular Atrophy to a Multi-Disciplinary Adult Program
  • Dr. Maryam Oskoui, MD, The Research Institute of the McGill University Health Centre
    Motor network connectivity in spinal muscular atrophy: new pathways for intervention

WATCH THE ANNOUNCEMENT

Important Update on Phone Solicitations

Muscular Dystrophy Canada does not use telemarketing services. You can support Fire Fighters and help them Fill the Boot for Muscular Dystrophy Canada and the individuals and families affected by neuromuscular disorders by going to filltheboot.ca.

STATEMENT REGARDING PHONE SOLICITATIONS

Several years ago, the Canadian Fire Fighter Curling Association (CFFCA) retained a telemarketing company to assist in fundraising for their annual curling event. A portion of the funds raised in past years were donated to MDC.

Muscular Dystrophy Canada can confirm a campaign soliciting donations for the Canadian Fire Fighter Curling Association has begun, seeking donations that support the Canadian Fire Fighter Curling Association.

In the past, we received complaints regarding the tone and approach of these solicitation calls and brought this to the attention of the CFFCA President.

Should you have any concerns or questions please contact the Canadian Fire Fighter Curling Association directly at cffca.ca.

We sincerely thank all of our generous supporters for making our work possible. Again, to help Fire Fighters #filltheboot go to filltheboot.ca.

New Ontario-led project to have national impact on newborn screening

Toronto, ON, March 9, 2022 – Muscular Dystrophy Canada (MDC) is proud to announce funding for a first-of-its-kind project to evaluate the cost-effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) in Canada, including early treatment. The innovative national project led by a team at the Children’s Hospital of Eastern Ontario (CHEO) will provide vital evidence for policy and decision makers and is expected to help expedite implementation of screening for SMA across the country.

“Discussions on adding new disorders to NBS panels often come down to cost and cost effectiveness: how much will screening for ‘X’ benefit patients and how does that compare to the health system costs? Unfortunately, Canadian health economic analyses are often not available to help answer this question. Our work will generate important information to support newborn screening policy decision making in Canada,” said Dr. Chakraborty, Medical Director of Newborn Screening Ontario (NSO) and project lead.

Today’s announcement is part of MDC’s collaboration with Novartis Pharmaceuticals Canada Inc. (Novartis) to make newborn screening for SMA a national reality. With Alberta and Saskatchewan recently initiating screening for SMA, the focus is now on full-implementation and providing information to support long-term sustainability of all projects.

“Generating this data will not only provide policy and decision makers the evidence they need to make NBS for SMA a national standard, but will also help foster collaboration and exchange of information across the country and can ultimately inform Canada’s Rare Disease Strategy” said Stacy Lintern, CEO, Muscular Dystrophy Canada. “We’re thrilled to be working with Novartis, committed government leaders, the SMA community and MDC’s dedicated Board of Directors, Fire Fighters, clients, donors and supporters to ensure all Canadians have access to the same healthcare, regardless of where they live.”

Access to newborn screening varies widely from province to province. In a progressive neuromuscular disorder like SMA, early diagnosis and prompt access to treatments lead to the best possible outcomes.

“Relocating during pregnancy opened my eyes to the existence of postal code healthcare in Canada,” said Lindsay Williamson, whose son Mason was diagnosed in 2021 with SMA at one month old. “Had we not moved from Ontario for work, our son’s condition would have been promptly picked up during newborn screening. This blood spot would have eliminated the need for a battery of costly medical tests and mitigated the stress of the diagnostic experience. I have no doubt this project will help guarantee families like ours get the information they need from day one.”

Further information on the impact of newborn screening for SMA and the projects funded to date is available at muscle.ca/services-support/newborn-screening/.

About Muscular Dystrophy Canada

Muscular Dystrophy Canada’s mission is to enhance the lives of those affected with neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for a cure through well-funded research. To learn more about Muscular Dystrophy Canada, please explore our website or call our toll-free number at 1-800-567-2873.

-30-

For more information:

Heather Rice
heather.rice@muscle.ca
902-440-3714

Newborns in Alberta can get screened for spinal muscular atrophy as part of pilot project with MDC

Statement from Stacey Lintern, Chief Executive Officer, Muscular Dystrophy Canada

February 28, 2022 – On this Rare Disease Day, MDC extends congratulations to Alberta on taking this important next step towards screening newborns for spinal muscular atrophy. Albertans will now have access to early diagnosis and treatments that will have life-changing results for individuals and families. This would not be possible without the partnership of Love for Lewiston for championing this important cause and helping influence positive change. Muscular Dystrophy Canada continues to work diligently with donors, provincial governments, partners and supporters to remove barriers so that screening for SMA becomes a reality across Canada.

If you would like to join Muscular Dystrophy Canada with ensuring Canadian babies have access to timely diagnosis and early access to care and treatment we would welcome your support. To learn more visit muscle.ca/services-support/newborn-screening/

 

Saskatchewan expanding newborn screening for Spinal Muscular Atrophy (SMA)

Statement from Stacey Lintern, Chief Executive Officer, Muscular Dystrophy Canada

Muscular Dystrophy Canada continues to work diligently with donors, provincial governments, partners and supporters to remove barriers so that screening for SMA in Canada is a reality. Growing evidence shows the profound impact newborn screening has on the quality of lives of children born with SMA, and their families. We know that for children affected by SMA, promising outcomes are possible with a timely diagnosis and early access to specialized care and treatment.

We applaud Saskatchewan for recognizing this and expanding their newborn screening panel to include testing for SMA as part of its newborn screening program.

To learn more about SMA newborn screening please visit muscle.ca/services-support/newborn-screening.

If you would like to join Muscular Dystrophy Canada with ensuring Canadian babies have access to timely diagnosis and early access to care and treatment we would welcome your support.

For more information, contact:

Stacey Lintern
CEO, Muscular Dystrophy Canada
647-284-8706
Stacey.Lintern@muscle.ca

Rare Disease Day 2022

For the upcoming #RareDiseaseDay, we asked clients “What do you wish you knew about [your neuromuscular disorder] when you were first diagnosed and how did you advocate for yourself along your neuromuscular journey?”

Dystrophinopathy | Kiana Bergen

Kiana Bergen shares, “One of the things I wish I’d known about Duchenne muscular dystrophy and related dystrophinopathies is this: as a child you have many doctors meeting with you but once you turn 18, you fall into a pit where you aren’t sure what to do or where to go. I also think it is important for those who are female carriers to check their heart – I started heart medication at age 15.

I am blessed with a family who supports me and stands up for me, especially my mom. She has also encouraged and inspired me to be an advocate for myself. It is definitely not easy, but it is worth it. It is important to focus on the why – because not everyone will understand what you’re going through and what you need. For rare conditions, like Duchenne and Becker muscular dystrophy, where there is little known by the public, there is limited information on the impacts on females. We need to share, raise awareness and not be afraid to ask for help.”

About Dystrophinopathies: Dystrophinopathies are a group of progressive neuromuscular disorders that are caused by spelling changes in the dystrophin gene. This gene is on the X chromosome; therefore, primarily males are impacted by dystrophinopathies, but female carriers can also exhibit symptoms. The more severe form is called Duchenne muscular dystrophy and the relatively milder form Becker muscular dystrophy. Symptoms may include frequent falls, difficulty getting up, enlarged calf muscles, cardiac complications, and trouble breathing as the disease progresses.

Friedreich’s Ataxia (FA) | Ethan and Kyle Valiquette

Ethan and Kyle Valliquette shared their experience.

Ethan and Kyle: “Friedreich’s Ataxia (FA) is degenerative and hits everyone differently. We wish we both knew how quickly we would lose our mobility. In the last two years, we went from walking to full time in a wheelchair.”

Ethan: “I was a double black diamond Snowboarder.”

Kyle: “And I was a wizard on the Ripstick and pretty good at drawing.”

Ethan and Kyle: “Had we known we would lose our coordination so fast we would have spent so much more time following our hobbies. Our friends helped us advocate, they were understanding and were always there for us. Our friends stuck with us through our loss of mobility. Now we encourage those friends to do what they are passionate about and make sure they follow through. FA may be rare, but it doesn’t have to be rare to have friends and support!”

About Friedreich ataxia (FA): FA is a genetic, progressive neuromuscular disorder that impacts the body’s nerves and symptoms typically start to show in childhood or adolescence Symptoms may include progressive difficulty in walking and poor balance (ataxia) along with impacts on swallowing, speaking and vision.

Undefined rare neuromuscular disorder | Dayle Sheehan

Dayle Sheehan shared, “I wish I had known what a full and beautiful life was ahead of me! I am blessed to have parents that advocated for me and taught me to do the same for myself. Today, I am grateful for the people who helped me live my best life: their support and love has allowed me to chase my dreams and to say ‘YES’ to many amazing opportunities.”

About Neuromuscular disorders (NMDs): NMDs can be hereditary or immune-mediated conditions where the primary effect is on the muscles, the neuromuscular junction, and/or peripheral nerves. There are many rare types of hereditary neuromuscular diseases for which the gene causing the disease has not been found, but it may be discovered in the future and often, individuals can go years without receiving a specific diagnosis. This proves the need for well-funded research to discover causes for neuromuscular disorders and to learn more about the ones we do know about so that Canadians can get a specific diagnosis and gain access to high-quality care and disease-modifying treatments.

Genetic Myopathy; myofibrillar myopathy | Felicia Assenza (@feliciaassenzand)

Felicia Assenza shared, “I wish I knew that I did not need to be fixed. I wish I knew that I was whole and amazing just the way I am, and to appreciate all of the lessons and growth along my neuromuscular journey. I advocate by doing my best to accept and love myself as I am, embrace the lessons, and encourage others to embrace themselves and their journeys too.”

About Myofibrillar myopathies: Myofibrillar myopathies are a group of neuromuscular disorders that affect various genes responsible for the health of muscle. They belong to the umbrella of genetic myopathies such as nemaline and congenital myopathy. Age of onset varies greatly depending on the exact gene that is impacted, but common symptoms may include muscle weakness including the heart, muscle stiffness and decreased muscle mass.

Facioscapulohumeral muscular dystrophy (FSHD) | Emily Caouette

Emily Caouette shared, “I wish I knew that diagnosis of Facioscapulohumeral muscular dystrophy FSHD does not mean a poor prognosis. There will always be daily struggles, but I learned through the patient community and extensive research that diet, exercise, environmental factors, and mental health play a very important role in managing symptoms and progression. I found a sense of purpose in advocating, by sharing my knowledge and experiences in support groups and establishing a peer support group on nutrition and supplementation.”

About Facioscapulohumeral muscular dystrophy (FSHD): FSHD is a neuromuscular disorder in which the muscles of the face, shoulder blades, and upper arms are among the most affected. The most probable cause of FSHD is a genetic change (mutation) that leads to inappropriate expression of the double homeobox protein 4 gene (DUX4) on chromosome 4. FSHD may present at any age and increase over time, but for the majority symptoms usually begin before age 20. Symptoms can include facial weakness, difficulties raising arms, forearm and abdominal weakness.

Charcot-Marie-Tooth (CMT) Disease | Victoria and Brittni Hudson

Victoria Hudson shared, “I wish I had known that my future did not rest on receiving a diagnosis of CMT, but on how I responded to that diagnosis. It is about learning to accept it and find a way to get on with the business of living with it. Both my daughter Brittni and I have CMT type 1A . Our doctor is not familiar with this and has not provided any information so I have advocated on both our behalf by seeking people that are aware of this condition. Through online webinars and other resources, I have tried to research as much about this as I can in order to find ways to improve the quality of our lives.”

About Charcot-Marie-Tooth (CMT): CMT is also called Hereditary Motor and Sensory Neuropathy (and historically peroneal muscular atrophy). There are a number of sub-types of CMT which are caused by changes in the genes that are responsible for creating and maintaining the myelin (insulating sheath around many nerves, increasing conductivity) and axonal structures. Symptoms of CMT include weakness or paralysis in feet and hands. This weakness can lead to toe-walking, foot drop, and frequent tripping, as well as impacted ability to feel heat, cold and touch.

Kennedy’s disease | Raymond Ricard

Raymond Ricard shared, “One of the main things I wished I knew about Kennedy’s Disease was the time: when would it start, how it would progress and how much I would digress over the years. Advocating for myself has been a bit hard. The only thing I could do was tell my employer what I had. It was taking a chance, but I was working with adults with disabilities and felt it was important to disclose.”

Kennedy’s disease: Kennedy’s disease is a neuromuscular disorder and is one form of X-linked bulbospinal muscular atrophy (BSMA or SMAX1). Kennedy’s disease typically impacts males between ages 30-60. Symptoms of BSMA may include muscle weakness, muscle cramps, fatigue, tremors and as the disorder progresses, other muscles can also be impacted such as those needed for speech, chewing and breathing.

Oculopharyngeal Muscular Dystrophy (OPMD) | Louis-Michel Guay

Louis-Michel Guay shared, “What I wish I had known about OPMD was that the speed of progression could be very different from one individual to another, even within the same family. Although my mother inherited a very slow form of the disease, I inherited a very fast form of the disease.

In terms of advocacy, when I contacted the neurology department at the Enfant-Jésus Hospital to request an early administration of the second dose of the COVID-19 vaccine, I was told without hesitation that I was not eligible. I then filed a complaint with the Complaints Commissioner of the Ministry of Health and Social Services and was also told that I was not eligible for advance delivery of my second dose. I did not get discouraged and filed a new complaint with the Québec Ombudsman, which I won. This is proof that you should never give up. It is very important to understand that I obtained an individual victory that did not benefit all those affected by OPMD in Quebec. Our next challenge will be to find a way to share information between those impacted, so that everyone can benefit from individual gains and discoveries.”

About Occulopharyngeal Muscular Dystrophy (OPMD): OPMD is a dominant genetic condition, which means that it can be inherited from either parent, and can impact men and women equally. It is caused by a genetic change in the PABPN1 gene, which leads to the production of a non-functional protein that forms clumps in the muscle cells. Symptoms typically present after 40 years of age and include muscle weakness around the upper eyelid, difficulty swallowing and muscle weakness in the limbs. OPMD is more common in the French-Canadian population in the province of Quebec.

Fran Cosper | Guillain Barré Syndrome

Fran Cosper shared, “I wish I knew that no matter how bad the situation can be, not to give up hope. Also, be positive – I often thought about what I did to cause GBS, but I’m not sure there is anything I could have done to avoid it as GBS is autoimmune in nature.

It is important to advocate for yourself – there were two individual instances when we called the doctors and told them our displeasure at how my family was told I would not walk again and how my wheelchair was being handled. It was important to use my voice and to be knowledgeable and stay in the loop on my care and rehabilitation. My wife and I, at every stage, made sure we understood what the process was and what we had to do. We took notes on everything. If it does not feel right, it is important to seek more information, get a better understanding and work to make it right.”

About Guillain-Barré syndrome (GBS): GBS is an autoimmune disorder that causes the immune system to attack the peripheral nerves, damaging the myelin sheath, which is the nerves’ protective covering. The age for which symptoms begin can vary widely depending on the individual but they are often quite sudden and unexpected. Symptoms of GBS may include muscle weakness, difficulty with vision and swallowing, and tingling in the extremities depending on the amount of nerve damage present.

Lindsay Williamson | Spinal Muscular Atrophy

Lindsay Williamson, mother of Mason shared, “When Mason was first diagnosed with Spinal muscular atrophy (SMA) at one month of age, I wish I knew just how far treatment has come and how much hope there is as a result. Not so long ago, families were told to enjoy the time they have with their child whereas today, we are working on strengthening the muscles Mason does have as we look towards milestones like rolling, sitting, crawling and maybe one day, first steps. We also never anticipated being a part of the most incredible national and global communities that we now can’t picture our life without.

Being a rare disease, our knowledge of SMA at the time of diagnosis was extremely limited, apart from the fact that it was only included in Newborn Screening in Ontario. Having relocated from that province during pregnancy opened my eyes to the existence of postal code healthcare in Canada resulting in feelings of guilt over our naivety that our child would get an equal start wherever they were born in this country. Had we never relocated for work, our son’s disease would have been caught almost immediately and our newborn spared from countless unnecessary tests, using up precious and often over-extended hospital resources. A delayed diagnosis means delayed treatment, and more time for irreversible damage to occur.”

“All of these realizations led us to begin asking questions in order to shine light on areas in need of improvement because although we cannot change our past, we do have the potential to ease the burden for those that follow. While some may call this advocacy, for our family, it helped us find peace in our circumstance and transform coincidence into purpose. Through our efforts to both understand and ascertain the best care for our son, we have also helped expedite access to treatment for another family, participated in a Newborn Screening expansion project, and actively shared our reality and progress with others in order to spread awareness while extending the same hope and support that we felt as new members in the SMA community. Although our journey is still in its infancy, finding both our voice and our village has given us confidence on Mason’s journey to make the most of whatever the future holds for him.”

About Spinal Muscular Atrophy (SMA): SMA is a genetic neuromuscular disorder caused by a shortage of a motor neuron protein called SMN – “survival of motor neuron.” This specific type of nerve cell in the spinal cord called motor neurons controls muscle movement. Without these motor neurons, muscles do not receive nerve signals that make muscles move. Muscles become smaller and weaker, which can affect a person’s ability to walk, speak, eat or breathe. Symptoms typically present in a child’s early years depending on their diagnosis. There are 4 types of SMA that vary based on the age that symptoms start to develop. Symptoms of SMA include progressive muscle weakness in the limbs and respiratory muscles.

Pompe disease | Alexandra Butler

Alexandra Butler shared, “I wish I knew that Pompe can impact each individual so differently and that early intervention is critical. I was extremely fortunate to have so many wonderful people in my corner when I started my journey as a Pompe patient – allowing those people to help guide and assist with advocating along my journey was a blessing. There is power in knowledge and numbers, learn from those diagnosed before you and never hesitate to reach out to those you love!”

About Pompe: Pompe disease is a neuromuscular disorder that belongs to a group of (hereditary) metabolic myopathies. In the case of Pompe, this disorder interfere with the processing of food (carbohydrates) for energy production. It affects mobility, muscle tone, and the respiratory system due to the build-up of glycogen (sugar) in the body. The build-up of glycogen in the body prevents the muscles from functioning well. Depending on the type of Pompe disease, symptoms can begin anywhere from birth to late adulthood and there can be variability in how it presents and progresses between individuals.

Give the gift of a new beginning

We didn’t know that with treatment her story could be different.
Lucy should have received treatment before symptoms appeared and thanks to the advocacy of MDC, other babies won’t have to wait.

Laura Van Doormaal

Imagine seeing your newborn’s health rapidly decline at three weeks of age. You had been watching them kick, cry, suck their thumb and feed wonderfully, but now you start to notice weakness in their arms and legs. Then, two weeks later, your perfectly healthy, full-term baby is struggling to feed and breathe, and you are receiving a diagnosis that includes the heart crushing words “rarely survive past two years”.

Laura and Scott Van Doormaal do not have to imagine this scenario. This is exactly what they went through when, at five weeks old, their daughter Lucy was diagnosed with Spinal Muscular Atrophy (SMA) Type 1.

You can help children, like Lucy, live life to the fullest by making a donation today!

Lucy began a treatment for SMA immediately and then at five months old, on September 9, 2020, she was selected to receive a new gene therapy. For the Van Doormaal family, this was a new start.

All of us at Muscular Dystrophy Canada (MDC) are grateful that Lucy had the opportunity for a new beginning, and for her medical team that made it possible. But we know not everyone has this experience.

It is because of generous donors like you that we’re able to advocate for earlier diagnoses of neuromuscular disorders across Canada, fund more research to improve treatment options and search for cures. We’re making progress, but there is so much more to do.

In a neuromuscular disorder like SMA, where time is of the essence, early diagnosis and prompt access to treatments are critical to achieving the best possible outcomes. Unfortunately, this is not the reality for most Canadians….yet.

Please consider making a gift today. Your donation will ensure that people like Lucy receive earlier diagnoses, and have access to important programs and services that can support their emotional, mental and physical health.

Make your gift today

Your gift gives families, like the Van Doormaals, a new beginning.

Today, although there is still a long road ahead, Lucy is thriving. At almost two years old, Lucy has started standing with support, communicating more and showing off her love of dancing. She has regained her ability to eat, and truly loves mealtime. Laura told us that:

“Early diagnosis and access to treatment has the biggest impact on the future for families who experience neuromuscular disorders like SMA. I know this is something MDC is passionate about.”

We know that access to treatment before symptoms appear can change a life. Together, we can ensure that screening and diagnoses are available as early as possible, even before 5 weeks of age. That’s why I’m asking you to make a donation today. Your support will mean a new beginning for people across the country.

You can help save lives.

I am grateful to each donor who has invested in our shared goals. You have already made a difference to our community. Thank you for supporting our important work and for your continued partnership.

Sincerely,

Stacey Lintern
Chief Executive Officer

Make your gift today

PS. Your gift today will help ensure people diagnosed with neuromuscular disorders receive the treatment they need as soon as possible, before it’s too late.

PPS. Making your donation is easy. Simply fill out the enclosed reply form and return it in the reply envelope, or make your gift online at muscle.ca/give. You can also call 1-800-567-2873 to make a gift by phone.